Dr. Phillip Shelton is a registered patent agent and a lawyer-in-training (4L) handling intellectual property matters related to the life sciences and biotech industries. His practice involves drafting and prosecuting patent applications, as well as performing due diligence investigations, patentability and invalidity assessments, freedom-to-operate analyses, and patent strategy counseling.
Exemplary technologies that Phillip has experience handling include cell-based therapeutics (e.g, stem cells and iPS cells), bioengineered microorganisms, CAR-T therapies, neoantigen identification, antibody therapeutics, xenotransplantation, AAV-based therapeutics, clinical diagnostics, pharmacodynamic and diagnostic biomarkers, mitochondrial replacement therapy, and peptide therapeutics, among others.
Prior to joining Jones Day, Phillip worked as a postdoctoral research associate in Jorge Moscat and Maria Diaz-Meco's lab in La Jolla, California, where he investigated the role of microRNAs and extracellular vesicles in promoting colorectal cancer metastases. His doctoral training in molecular toxicology was focused on oncogenic signal transduction pathways responsible for hyper activating the master regulator of antioxidant responses: NRF2. Phillip has coauthored several publications and presented at international research conferences.
Publications Prior to Jones Day
Simultaneous Loss of Both Atypical Protein Kinase C Genes in the Intestinal Epithelium Drives Serrated Intestinal Cancer by Impairing Immunosurveillance, Immunity, 49(6):1132-1147
Metabolic reprogramming of the tumor microenvironment by p62 and its partners, Biochim Biophys Acta Rev Cancer, 1870(1):88-95
The Secretion of miR-200s by a PKCζ/ADAR2 Signaling Axis Promotes Liver Metastasis in Colorectal Cancer, Cell Rep., 23(4):1178-1191
Repression of Intestinal Stem Cell Function and Tumorigenesis through Direct Phosphorylation of β-Catenin and Yap by PKCζ, Cell Rep., 10(5):740-754
Reactivation of estrogen receptor α by vorinostat sensitizes mesenchymal-like triple-negative breast cancer to aminoflavone, a ligand of the aryl hydrocarbon receptor, PLoS One, 13;8(9):e74525
The transcription factor NF-E2-related factor 2 (Nrf2): a protooncogene?, FASEB J, Feb;27(2):414-23
- University of San Diego (currently attending law school with expected graduation in 2022); University of Maryland (Ph.D. in Toxicology 2013; M.S. in Molecular Medicine 2009); Indiana University (B.S. in Biology 2006)
- Registered to practice before the United States Patent and Trademark Office. Not licensed to practice by the State Bar of California.